Thyrocare Technologies Limited has informed the Exchange regarding Press release on Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.3%1-day move

₹472.50

prior close

₹493.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+4.2+5.4+5.2+3.0+1.3-0.1+1.2-0.5-2.4-0.7+10.1+14.2+10.9—

Up moveDown movePending

AI summary

Thyrocare Technologies reported strong Q4FY26 results with consolidated revenue of INR 223.95 crore, up 20% year-on-year, driven by 21% growth in the Pathology segment. Test volumes reached 59.0 million in Q4, marking a 29% YoY growth. EBITDA rose 31% YoY to INR 75.09 crore, while Profit After Tax surged 128% YoY to INR 48.70 crore. For the full year FY26, revenue grew 21% to INR 829.04 crore, EBITDA increased 38% to INR 262.04 crore, and PAT grew 81% to INR 162.85 crore. The company expanded its specialty portfolio with advanced allergy testing and entered genomics with NIPT launch.

Likely market impact

Strong operational performance with significant profit growth and margin expansion indicates improved operational efficiency and scale benefits, which is positive for shareholders.